US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

iShares Neuroscience and Healthcare ETF

37.31

-0.1119-0.30%

Volume:2K

Turnover:64.61K

Market Cap:7.46M

PE:- -

High:37.75

Open:37.31

Low:37.31

Close:37.43

52wk High:43.01

52wk Low:25.42

Shares:200.00K

Float Shares:200.00K

Volume Ratio:1.12

T/O Rate:0.86%

Dividend:0.32

Dividend Rate:0.86%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Praxis Precision Q2 Operating Expenses USD 96.904 Million

THOMSON REUTERS

Viridian Therapeutics Q2 Net Loss Widens as Lumvoa Launch Lifts Costs

Climb Bio Q2 Net Loss Widens on Pipeline Advancement

Scholar Rock Q2 Net Loss Narrows

Scholar Rock Holding Q2 EPS $(0.84) Beats $(0.85) Estimate; Cash Balance Of $492M

Benzinga Earnings

\tScholar Rock Holding Scholar Rock Holding Q2 Net Income USD -109.896 Million

\tSCHOLAR Rock Holding Q2 EPS Usd -0.84

THOMSON REUTERS

Dianthus Therapeutics, Inc. : H.c. Wainwright Raises Target Price to $158 from $130

THOMSON REUTERS

Haidian District in Beijing Accelerates Development as a Brain-Computer Interface Hub, Housing Nearly 60% of Core Companies Nationwide

Dianthus Therapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Arcus Biosciences Q2 Revenue Falls Sharply on Lower License Income

Enliven Therapeutics Q2 Net Loss Widens on Higher Expenses

Black Diamond Therapeutics Q2 Net Loss Narrows Year over Year

EyePoint Pharmaceuticals Q2 Revenue Drops on Lower License Income

Seres Therapeutics Q2 Net Income Turns Positive on VOWST Sale Gain

Analysts Conflicted on These Healthcare Names: Dianthus Therapeutics (DNTH) and American Well (AMWL)

Analysts Offer Insights on Healthcare Companies: Dianthus Therapeutics (DNTH) and Viridian Therapeutics (VRDN)

Dianthus Therapeutics Q2 Net Loss Widens as R&D Costs Rise

Praxis Precision Medicines Grants 7,318 RSUs to 29 New Employees Under 2024 Inducement Plan

Dianthus Therapeutics - Reports $1.20 Bln Cash as of June 30, 2026, Provides Expected Runway into 2030

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrnexa.com/stock/IBRN/news?page=8"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"IBRN","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IBRN\",,,,,undefined,":{"symbol":"IBRN","market":"US","secType":"STK","nameCN":"iShares Neuroscience and Healthcare ETF","latestPrice":37.3143,"timestamp":1789416000000,"preClose":37.4262,"halted":0,"volume":1718,"delay":0,"changeRate":-0.0029898840918928062,"floatShares":200000,"shares":200000,"eps":0,"marketStatus":"Pre-Mkt","change":-0.1119,"latestTime":"09-15 04:31:03 EDT","open":37.31,"high":37.745,"low":37.31,"amount":64609,"amplitude":0.011623,"askPrice":59.32,"askSize":100,"bidPrice":33.51,"bidSize":50,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1789479000000},"marketStatusCode":1,"adr":0,"exchange":"ARCA","adjPreClose":37.3143,"sharesOutstanding":150000,"nav":37.384466,"aum":7476893.2,"dividendRate":0.008603,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":37.5999,"preClose":37.3143,"latestTime":"16:10 EDT","volume":8,"amount":298.4058,"timestamp":1789416603823,"change":0.2856,"changeRate":0.007654,"amplitude":0},"volumeRatio":1.1163092482270598,"impliedVol":0.1627,"impliedVolPercentile":0.856},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IBRN\",,,,,undefined,":{"symbol":"IBRN","floatShares":200000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.1163092482270598,"shares":200000,"dividePrice":0.321,"high":37.745,"amplitude":0.011623,"preClose":37.4262,"low":37.31,"week52Low":25.4196,"pbRate":"--","week52High":43.01,"institutionHeld":0,"latestPrice":37.3143,"committee":-0.333333,"eps":0,"divideRate":0.008603,"volume":1718,"delay":0,"ttmEps":0,"open":37.31,"prevYearClose":32.3193,"prevWeekClose":37.4262,"prevMonthClose":38.9601,"prevQuarterClose":38.8263,"fiveDayClose":39.0596,"twentyDayClose":39.1355,"sixtyDayClose":35.5221},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IBRN\",params:#limit:5,,,undefined,":[{"date":"2025-12-16","symbol":"IBRN","amount":0.319807,"announcedDate":"2025-12-15","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-16","defaultRemindTime":1765895400000,"name":"iShares Neuroscience and Healthcare ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-19","payableDate":"2025-12-16","currency":"USD","dateTimestamp":1765861200000,"payDate":"2025-12-19"},{"date":"2024-12-17","symbol":"IBRN","amount":0.10114,"announcedDate":"2024-12-16","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-17","defaultRemindTime":1734445800000,"name":"iShares Neuroscience and Healthcare ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-20","payableDate":"2024-12-17","currency":"USD","dateTimestamp":1734411600000,"payDate":"2024-12-20"},{"date":"2023-12-20","symbol":"IBRN","amount":0.006303,"announcedDate":"2023-12-19","type":"dividend","market":"US","newRecordDate":"2023-12-21","defaultRemindTime":1703082600000,"name":"iShares Neuroscience and Healthcare ETF","recordDate":"2023-12-27","payableDate":"2023-12-21","currency":"USD","dateTimestamp":1703048400000,"payDate":"2023-12-27"},{"date":"2023-06-07","symbol":"IBRN","amount":0.008241,"announcedDate":"2023-05-12","type":"dividend","market":"US","newRecordDate":"2023-06-08","defaultRemindTime":1686144600000,"name":"iShares Neuroscience and Healthcare ETF","recordDate":"2023-06-13","payableDate":"2023-06-08","currency":"USD","dateTimestamp":1686110400000,"payDate":"2023-06-13"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IBRN\",market:\"US\",,,undefined,":[{"executeDate":"2023-06-07","recordDate":"2023-06-08","paymentDate":"2023-06-13","value":0.008241,"currency":"USD"},{"executeDate":"2023-12-20","recordDate":"2023-12-21","paymentDate":"2023-12-27","value":0.006303,"currency":"USD"},{"executeDate":"2024-12-17","recordDate":"2024-12-17","paymentDate":"2024-12-20","value":0.10114,"currency":"USD"},{"executeDate":"2025-12-16","recordDate":"2025-12-16","paymentDate":"2025-12-19","value":0.319807,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IBRN\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IBRN\",pageSize:20,pageCount:8,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2657366906","title":"Praxis Precision Q2 Operating Expenses USD 96.904 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2657366906","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657366906?lang=en_us&edition=fundamental","pubTime":"2026-08-06 20:00","pubTimestamp":1786017602,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nPLX4G8G05:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IE0002141913.USD","IE0009355771.USD","IE00BJJMRZ35.SGD","PRAX","BK4139","IBRN","LU0320765992.SGD","IE00BJT1NW94.SGD","IE00B2B36J28.USD","LU0109394709.USD","IE00B4R5TH58.HKD","LU0889565916.HKD","IE00BFTCPJ56.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657635318","title":"Viridian Therapeutics Q2 Net Loss Widens as Lumvoa Launch Lifts Costs","url":"https://stock-news.laohu8.com/highlight/detail?id=2657635318","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657635318?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:36","pubTimestamp":1786016160,"startTime":"0","endTime":"0","summary":"Viridian Therapeutics Q2 net loss widens as Lumvoa launch lifts costsOverviewU.S. biotech firm's Q2 net loss widened yr/yr as Lumvoa launch drove higher SG&A costsCompany ended Q2 with $981.5 mln in c","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL1N4430IF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MNKD","BK4584","IBRN","VRDN","BK4139","DNTH","BK4007","OCUL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657331716","title":"Climb Bio Q2 Net Loss Widens on Pipeline Advancement","url":"https://stock-news.laohu8.com/highlight/detail?id=2657331716","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657331716?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:29","pubTimestamp":1786015790,"startTime":"0","endTime":"0","summary":"Climb Bio Q2 net loss widens on pipeline advancementOverviewUS biotechnology firm's Q2 net loss widened yr/yr as operating expenses increasedCompany completed $110 mln private placement, extending cas","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL1N4430JV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLYM","DNTH","TYRA","IBRN","ELVN","BK4539","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657692633","title":"Scholar Rock Q2 Net Loss Narrows","url":"https://stock-news.laohu8.com/highlight/detail?id=2657692633","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657692633?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:22","pubTimestamp":1786015339,"startTime":"0","endTime":"0","summary":"Scholar Rock Q2 net loss narrowsOverviewUS biopharmaceutical firm's Q2 net loss narrowed slightly yr/yr with no revenue recordedOperating expenses for Q2 fell, driven by reduced research and developme","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL1N4430J6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4584","CMPS","IBRN","SRRK","BDTX","MNKD","THNR","BK4139","PSIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657638693","title":"Scholar Rock Holding Q2 EPS $(0.84) Beats $(0.85) Estimate; Cash Balance Of $492M","url":"https://stock-news.laohu8.com/highlight/detail?id=2657638693","media":"Benzinga Earnings","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657638693?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:04","pubTimestamp":1786014281,"startTime":"0","endTime":"0","summary":"Scholar Rock Holding (NASDAQ:SRRK) reported quarterly losses of $(0.84) per share which beat the analyst consensus estimate of $(0.85) by 1.18 percent. This is a 14.29 percent increase over losses of $(0.98) per share","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/08/60987314/scholar-rock-holding-q2-eps-0-84-beats-0-85-estimate-cash-balance-492m","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SRRK","THNR","IBRN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657638637","title":"\\tScholar Rock Holding Scholar Rock Holding Q2 Net Income USD -109.896 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2657638637","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657638637?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:01","pubTimestamp":1786014061,"startTime":"0","endTime":"0","summary":"BRIEF-\\tScholar Rock Holding Scholar Rock Holding Q2 Net Income USD -109.896 MillionAug 06 (Reuters) - \\tScholar Rock Holding Scholar Rock Holding Q2 income from operations USD -108.901 million.Scholar Rock Holding Q2 operating expenses USD 108.901 million","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nPLXM0XL7B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["THNR","IBRN","SRRK","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657512633","title":"\\tSCHOLAR Rock Holding Q2 EPS Usd -0.84","url":"https://stock-news.laohu8.com/highlight/detail?id=2657512633","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657512633?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:00","pubTimestamp":1786014002,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nPLXM0XL7B:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IBRN","SRRK","THNR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657042684","title":"Dianthus Therapeutics, Inc. : H.c. Wainwright Raises Target Price to $158 from $130","url":"https://stock-news.laohu8.com/highlight/detail?id=2657042684","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657042684?lang=en_us&edition=fundamental","pubTime":"2026-08-06 18:09","pubTimestamp":1786010947,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nAZN4TC72O:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","IBRN","DNTH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103378863","title":"Haidian District in Beijing Accelerates Development as a Brain-Computer Interface Hub, Housing Nearly 60% of Core Companies Nationwide","url":"https://stock-news.laohu8.com/highlight/detail?id=1103378863","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1103378863?lang=en_us&edition=fundamental","pubTime":"2026-08-06 15:58","pubTimestamp":1786003083,"startTime":"0","endTime":"0","summary":"The Zhongguancun Science City Management Committee recently disclosed that Haidian District in Beijing has gathered over 30 core brain-computer interface (BCI) companies, accounting for nearly 60% of...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MNTL","IBRN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657576639","title":"Dianthus Therapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2657576639","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657576639?lang=en_us&edition=fundamental","pubTime":"2026-08-06 05:01","pubTimestamp":1785963702,"startTime":"0","endTime":"0","summary":"Dianthus Therapeutics Inc reports results for the quarter ended June 30 - Earnings SummaryDianthus Therapeutics IncDNTH.OQreported a quarterly adjusted loss of 90 cents per share for the quarter ended","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nL8N4423HL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DNTH","BK4139","IBRN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657575672","title":"Arcus Biosciences Q2 Revenue Falls Sharply on Lower License Income","url":"https://stock-news.laohu8.com/highlight/detail?id=2657575672","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657575672?lang=en_us&edition=fundamental","pubTime":"2026-08-06 04:47","pubTimestamp":1785962871,"startTime":"0","endTime":"0","summary":"Arcus Biosciences Q2 revenue falls sharply on lower license incomeOverviewU.S. biopharma firm's Q2 revenue fell sharply yr/yr due to prior one-time license revenueCompany posted Q2 net loss as R&D exp","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nL1N4421DV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU0320765992.SGD","DNTH","BK4588","RCUS","EYPT","IBRN","LU0109394709.USD","BK4539","LU0889565916.HKD","BK4563","BK4585","BK4007","IMRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657578328","title":"Enliven Therapeutics Q2 Net Loss Widens on Higher Expenses","url":"https://stock-news.laohu8.com/highlight/detail?id=2657578328","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657578328?lang=en_us&edition=fundamental","pubTime":"2026-08-06 04:18","pubTimestamp":1785961100,"startTime":"0","endTime":"0","summary":"Enliven Therapeutics Q2 net loss widens on higher expensesOverviewUS biopharmaceutical firm's Q2 net loss widened yr/yr as operating expenses increasedCompany announced positive Phase 1 clinical data ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nL1N4421BH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DNTH","TYRA","IBRN","BK4139","ELVN","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657352038","title":"Black Diamond Therapeutics Q2 Net Loss Narrows Year over Year","url":"https://stock-news.laohu8.com/highlight/detail?id=2657352038","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657352038?lang=en_us&edition=fundamental","pubTime":"2026-08-06 04:08","pubTimestamp":1785960515,"startTime":"0","endTime":"0","summary":"Black Diamond Therapeutics Q2 net loss narrows year over yearOverviewUS oncology developer's Q2 net loss narrowed yr/yrCompany presented positive Phase 2 silevertinib results in NSCLC at ASCO 2026Cash","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nL1N4421AH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMRX","BDTX","TRDA","IBRN","BK4563","BK4139","DNTH","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657549329","title":"EyePoint Pharmaceuticals Q2 Revenue Drops on Lower License Income","url":"https://stock-news.laohu8.com/highlight/detail?id=2657549329","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657549329?lang=en_us&edition=fundamental","pubTime":"2026-08-05 19:24","pubTimestamp":1785929053,"startTime":"0","endTime":"0","summary":"EyePoint Pharmaceuticals Q2 revenue drops on lower license incomeOverviewUS retinal disease drug developer's Q2 revenue fell sharply yr/yr on lower license revenueQ2 operating expenses rose, reflectin","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nL1N4420J5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EYPT","BK4007","DNTH","LU0889565916.HKD","OCUL","LU0320765992.SGD","IBRN","STOK","BK4585","BK4139","BK4588","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657354674","title":"Seres Therapeutics Q2 Net Income Turns Positive on VOWST Sale Gain","url":"https://stock-news.laohu8.com/highlight/detail?id=2657354674","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657354674?lang=en_us&edition=fundamental","pubTime":"2026-08-05 19:19","pubTimestamp":1785928770,"startTime":"0","endTime":"0","summary":"Seres Therapeutics Q2 net income turns positive on VOWST sale gainOverviewUS biotechnology firm's Q2 net income turned positive, driven by VOWST business sale gainOperating expenses for Q2 fell yr/yr ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nL1N4420IF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MCRB","KROS","BK4139","IBRN","DNTH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657953475","title":"Analysts Conflicted on These Healthcare Names: Dianthus Therapeutics (DNTH) and American Well (AMWL)","url":"https://stock-news.laohu8.com/highlight/detail?id=2657953475","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657953475?lang=en_us&edition=fundamental","pubTime":"2026-08-05 08:10","pubTimestamp":1785888606,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Dianthus Therapeutics (DNTH) and American Well (AM...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-dianthus-therapeutics-dnth-and-american-well-amwl-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-dianthus-therapeutics-dnth-and-american-well-amwl-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4167","BK4585","XLV","BK4588","XBI","BK4581","HCSG","LU0128526141.USD","IBRN","AMWL","DNTH","LU0029874061.USD","BK4137","LABU","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657567780","title":"Analysts Offer Insights on Healthcare Companies: Dianthus Therapeutics (DNTH) and Viridian Therapeutics (VRDN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2657567780","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657567780?lang=en_us&edition=fundamental","pubTime":"2026-08-05 05:20","pubTimestamp":1785878408,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Dianthus Therapeutics (DNTH) and Viridian Therapeuti...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-dianthus-therapeutics-dnth-and-viridian-therapeutics-vrdn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-dianthus-therapeutics-dnth-and-viridian-therapeutics-vrdn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4137","BK4588","BK4585","LU0128526141.USD","HCSG","VRDN","BK4139","LABU","IBRN","LU0029874061.USD","XLV","XBI","DNTH","BK4581"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657569783","title":"Dianthus Therapeutics Q2 Net Loss Widens as R&D Costs Rise","url":"https://stock-news.laohu8.com/highlight/detail?id=2657569783","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657569783?lang=en_us&edition=fundamental","pubTime":"2026-08-05 04:09","pubTimestamp":1785874166,"startTime":"0","endTime":"0","summary":"Dianthus Therapeutics Q2 net loss widens as R&D costs riseOverviewUS biotech firm reported Q2 net loss widened to $50.2 mlnOperating expenses for Q2 rose, driven by higher R&D costs for clinical progr","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nL1N44113F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","DNTH","KROS","IBRN","PVLA","BK4139","DSGN","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657693385","title":"Praxis Precision Medicines Grants 7,318 RSUs to 29 New Employees Under 2024 Inducement Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2657693385","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657693385?lang=en_us&edition=fundamental","pubTime":"2026-08-05 04:02","pubTimestamp":1785873760,"startTime":"0","endTime":"0","summary":"Praxis Precision Medicines grants 7,318 RSUs to 29 new employees under 2024 inducement planPraxis Precision Medicines granted restricted stock units covering 7,318 common shares to 29 new non-executiv","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nNDL2Gq3xh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014021.USD","BK4585","IE00BN0W2V16.EUR","BK4139","IE00B4R5TH58.HKD","LU0314104364.USD","IE00BJT1NW94.SGD","BCDF","LU0320765992.SGD","IE00BN0W2T93.GBP","IE00B64PRP62.GBP","LU0889565916.HKD","LU2210149790.SGD","IE00BKPKM429.USD","SG9999014005.SGD","IE0002141913.USD","IE0009355771.USD","IE00B3QW5Z07.USD","NDAQ","BK4588","PRAX","IE00BFTCPJ56.SGD","SG9999014013.SGD","IBRN","LU2210150020.SGD","IE00BJJMRZ35.SGD","LU0109394709.USD","IE00B2B36J28.USD","LU2095319765.USD","IE00BN0W2W23.USD","IE00BGHQF748.EUR","BK4112","SG9999014039.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657856473","title":"Dianthus Therapeutics - Reports $1.20 Bln Cash as of June 30, 2026, Provides Expected Runway into 2030","url":"https://stock-news.laohu8.com/highlight/detail?id=2657856473","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657856473?lang=en_us&edition=fundamental","pubTime":"2026-08-05 04:01","pubTimestamp":1785873662,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nTUA59Z0BL:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["DNTH","BK4139","IBRN"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":8,"totalSize":200,"code":"91000000","status":"200"}]}}